The complement system and its role in the pathogenesis of periodontitis: Current concepts

Journal of Periodontal Research

Volumn 50, Issue 3, 2015, Pages 283-293

  Damgaard, C ^a,b,c   Holmstrup, P ^a   Van Dyke, T E ^c   Nielsen, C H ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Rigshospitalet   (Denmark)

^c FORSYTH INSTITUTE   (United States)

Author keywords

Biofilm; Complement; Humans; Inflammation; Periodontitis

Indexed keywords

COMPLEMENT;

BACTERIUM; BIOFILM; COMPLEMENT ACTIVATION; HUMAN; IMMUNE EVASION; IMMUNOLOGY; MICROBIOLOGY; PERIODONTAL POCKET; PERIODONTITIS;

BACTERIA; BIOFILMS; COMPLEMENT ACTIVATION; COMPLEMENT SYSTEM PROTEINS; HUMANS; IMMUNE EVASION; PERIODONTAL POCKET; PERIODONTITIS;

EID: 84928650746     PISSN: 00223484     EISSN: 16000765     Source Type: Journal    
DOI: 10.1111/jre.12209     Document Type: Review

References (136)

1. Eherlich P, Morgenroth J. Zur theorie der lysinwirkung. Berlin Klin Wochenschr 1899;36:6-9.
2. Chaplin H Jr. Review: the burgeoning history of the complement system 1888-2005. Immunohematology 2005;21:85-93.
3. Lachmann P. Complement before molecular biology. Mol Immunol 2005;43:496-508.
4. Walport MJ. Complement. First of two parts. N Engl J Med 2001;344:1058-1066.
5. Walport MJ. Complement. Second of two parts. N Engl J Med 2001;344:1140-1144.
6. Le Frie G, Kemper C. Complement: coming full circle. Arch Immunol Ther Exp (Warsz) 2009;57:393-407.
7. Ricklin D, Hajishengallis G, Yang K, Lambris JD. Complement: a key system for immune surveillance and homeostasis. Nat Immunol 2010;11:785-797.
8. Amano A. Host-parasite interactions in periodontitis: subgingival infection and host sensing. Periodontol 2000 2010;52:7-11.
9. Maynard CL, Elson CO, Hatton RD, Weaver CT. Reciprocal interactions of the intestinal microbiota and immune system. Nature 2012;489:231-241.
10. Hajishengallis G, Lambris JD. Complement and dysbiosis in periodontal disease. Immunobiology 2012;217:1111-1116.
11. Bartold PM, Van Dyke TE. Periodontitis: a host-mediated disruption of microbial homeostasis. Unlearning learned concepts. Periodontol 2000 2013;62:203-217.
12. American Academy of Periodontology. Parameters on aggressive periodontitis. J Periodontol 2000;71:867-869.
13. Meng H, Xu L, Li Q, Han J, Zhao Y. Determinants of host susceptibility in aggressive periodontitis. Periodontol 2000 2007;43:133-159.
14. Fredman G, Oh SF, Ayilavarapu S, Hasturk H, Serhan CN, Van Dyke TE. Impaired phagocytosis in localized aggressive periodontitis: rescue by Resolvin E1. PLoS ONE 2011;6:e24422. doi:10.1371/journal.pone.0024422.
15. Camous L, Roumenina L, Bigot S et al. Complement alternative pathway acts as a positive feedback amplification of neutrophil activation. Blood 2011;117:1340-1349.
16. Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL Jr. Microbial complexes in subgingival plaque. J Clin Periodontol 1998;25:134-144.
17. Darveau RP. Periodontitis: a polymicrobial disruption of host homeostasis. Nat Rev Microbiol 2010;8:481-490.
18. Ebersole JL, Taubman MA. The protective nature of host responses in periodontal diseases. Periodontol 2000 1994;5:112-141.
19. Madianos PN, Bobetsis YA, Kinane DF. Generation of inflammatory stimuli: how bacteria set up inflammatory responses in the gingiva. J Clin Periodontol 2005;32:57-71.
20. Liu YC, Lerner UH, Teng YT. Cytokine responses against periodontal infection: protective and destructive roles. Periodontol 2000 2010;52:163-206.
21. Paster BJ, Boches SK, Galvin JL et al. Bacterial diversity in human subgingival plaque. J Bacteriol 2001;183:3770-3783.
22. Holt SC, Ebersole JL. Porphyromonas gingivalis, Treponema denticola, and Tannerella forsythia: the "red complex", a prototype polybacterial pathogenic consortium in periodontitis. Periodontol 2000 2005;38:72-122.
23. Hajishengallis G. Complement and periodontitis. Biochem Pharmacol 2010;80:1992-2001.
24. Hajishengallis G, Liang S, Payne MA et al. Low-abundance biofilm species orchestrates inflammatory periodontal disease through the commensal microbiota and complement. Cell Host Microbe 2011;10:497-506.
25. Darveau RP, Hajishengallis G, Curtis MA. Porphyromonas gingivalis as a potential community activist for disease. J Dent Res 2012;91:816-820.
26. Forner L, Larsen T, Kilian M, Holmstrup P. Incidence of bacteremia after chewing, tooth brushing and scaling in individuals with periodontal inflammation. J Clin Periodontol 2006;33:401-407.
27. Tomás I, Diz P, Tobías A, Scully C, Donos N. Periodontal health status and bacteraemia from oral activities: systematic review/meta-analysis. J Clin Periodontol 2012;39:213-228.
28. Santos Tunes R, Foss-Freitas MC, Nogueira-Filho GR. Impact of periodontitis on the diabetes-related inflammatory status. J Can Dent Assoc 2010;76:a35.
29. Koromantzos PA, Makrilakis K, Dereka X, Katsilambros N, Vrotsos IA, Madianos PN. A randomized, controlled trial on the effect of non-surgical periodontal therapy in patients with type 2 diabetes. J Clin Periodontol 2011;38:142-147.
30. Chapple IL, Genco R, working group 2 of the joint EFP/AAP workshop. Diabetes and periodontal diseases: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol 2013;84:S106-S112.
31. Belstrøm D, Damgaard C, Nielsen CH, Holmstrup P. Does a causal relation between cardiovascular disease and periodontitis exist? Microbes Infect 2012;14:411-418.
32. Tonetti MS, Van Dyke TE. Periodontitis and atherosclerotic caridovascular disease: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol 2013;84:24-29.
33. Kaur S, White S, Bartold PM. Periodontal disease and rheumatoid arthritis: a systematic review. J Dent Res 2013;92:399-408.
34. Sanz M, Kornman K, working group 3 of the joint EFP/AAP workshop. Periodontitis and adverse pregnancy outcomes: consensus report of the Joint EFP/AAP Workshop on Periodontitis and Systemic Diseases. J Periodontol 2013;84:S164-S169.
35. Köhl J. Self, non-self, and danger: a complementary view. Adv Exp Med Biol 2006;586:71-94.
36. Markiewski MM, Lambris JD. The role of complement in inflammatory diseases from behind the scenes into the spotlight. Am J Pathol 2007;171:715-727.
37. Wallis R, Mitchell DA, Schmid R, Schwaeble WJ, Keeble AH. Paths reunited: initiation of the classical and lectin pathways of complement activation. Immunobiology 2010;215:1-11.
38. Nayak A, Pednekar L, Reid KB, Kishore U. Complement and non-complement activating functions of C1q: a prototypical innate immune molecule. Innate Immun 2012;18:350-363.
39. Shishido SN, Varahan S, Yuan K, Li X, Fleming SD. Humoral innate immune response and disease. Clin Immunol 2012;144:142-158.
40. Harboe M, Mollnes TE. The alternative complement pathway revisited. J Cell Mol Med 2008;12:1074-1084.
41. Zhang W, Lucisani YM, Lachmann PJ. Complement in IgA immune-complex-induced neutrophil activation. Biochem Soc Trans 1997;25:462-466.
42. Karsten CM, Köhl J. The immunoglobulin, IgG Fc receptor and complement triangle in autoimmune disease. Immunobiology 2012;217:1067-1076.
43. Kimura Y, Miwa T, Zhou L, Song WC. Activator-specific requirement of properdin in the initiation and amplification of the alternative pathway complement. Blood 2008;111:732-740.
44. Spitzer D, Mitchell LM, Atkinson JP, Hourcade DE. Properdin can initiate complement activation by binding specific target surfaces and providing a platform for de novo convertase assembly. J Immunol 2007;179:2600-2608.
45. Zipfel PF, Skerka C. Complement regulators and inhibitory proteins. Nat Rev Immunol 2009;9:729-740.
46. Ali YM, Lynch NJ, Haleem KS et al. The lectin pathway of complement activation is a critical component of the innate immune response to pneumococcal infection. PLoS Pathog 2012;8:e1002793. doi:10.1371/journal.ppat.1002793.
47. Ma YJ, Skjoedt MO, Garred P. Collectin-11/MASP complex formation triggers activation of the lectin complement pathway-the fifth lectin pathway initiation complex. J Innate Immun 2013;5:242-250.
48. Matsushita M, Endo Y, Fujita T. Cutting edge: complement-activating complex of ficolin and mannose-binding lectin-associated serine protease. J Immunol 2000;164:2281-2284.
49. Nielsen CH, Antonsen S, Matthiesen SH, Leslie RG. The roles of complement receptors type 1 (CR1, CD35) and type 3 (CR3, CD11b/CD18) in the regulation of the immune complex-elicited respiratory burst of polymorphonuclear leukocytes in whole blood. Eur J Immunol 1997;27:2914-2919.
50. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. J Exp Med 1980;152:20-30.
51. Chevalier J, Kazatchkine MD. Distribution in clusters of complement receptor one (CR1) on human erythrocytes. J Immunol 1989;142:7016-7029.
52. Leslie RG, Nielsen CH. The classical and alternative pathways of complement activation play distinct roles in spontaneous C3 fragment deposition and membrane attack complex (MAC) formation on human B lymphocytes. Immunology 2004;111:86-90.
53. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. Immunity 2012;37:199-207.
54. He JQ, Wiesmann C, van Lookeren Campagne M. A role of macrophage complement receptor CRIg in immune clearance and inflammation. Mol Immunol 2008;45:4041-4047.
55. Pangburn MK. Host recognition and target differentiation by factor H, a regulator of the alternative pathway of complement. Immunopharmacology 2000;49:149-157.
56. Kim KH, Choi BK, Song KM et al. CRIg signals induce anti-intracellular bacterial phagosome activity in a chloride intracellular channel 3-dependent manner. Eur J Immunol 2013;43:667-678.
57. Reynes M, Aubert JP, Cohen JH et al. Human follicular dendritic cells express CR1, CR2, and CR3 complement receptor antigens. J Immunol 1985;135:2687-2694.
58. Fischer E, Delibrias C, Kazatchkine MD. Expression of CR2 (the C3dg/EBV receptor, CD21) on normal human peripheral blood T-lymphocytes. J Immunol 1991;146:865-869.
59. Nielsen CH, Leslie RG. Complement's participation in acquired immunity. J Leukoc Biol 2002;72:249-261.
60. Lutz HU, Jelezarova E. Complement amplification revisited. Mol Immunol 2006;43:2-12.
61. Li R, Coulthard LG, Wu MC, Taylor SM, Woodruff TM. C5L2: a controversial receptor of complement anaphylatoxin, C5a. FASEB J 2013;27:855-864.
62. Ward PA. Functions of C5a receptors. J Mol Med 2009;97:375-378.
63. Assuma R, Oates T, Cochran D, Amar S, Graves DT. IL-1 and TNF antagonists inhibit the inflammatory response and bone loss in experimental periodontitis. J Immunol 1998;160:403-409.
64. Pobanz JM, Reinhardt RA, Koka S, Sanderson SD. C5a modulation of interleukin-1 beta-induced interleukin-6 production by human osteoblast-like cells. J Periodont Res 2000;35:137-145.
65. Vernal R, Dutzan N, Chaparro A, Puente J, Valenzuela MA, Gamonal J. Levels of interleukin-17 in gingival crevicular fluid and in supernatants of cellular cultures of gingival tissue from patients with chronic periodontitis. J Clin Periodontol 2005;32:383-389.
66. Graves D. Cytokines that promote periodontal tissue destruction. J Periodontol 2008;79:1585-1591.
67. Eskan MA, Jotwani R, Abe T et al. The leukocyte integrin antagonist Del-1 inhibits IL-17-mediated inflammatory bone loss. Nat Immunol 2012;13:465-473.
68. Abe T, Hosur KB, Hajishengallis E et al. Local complement-targeted intervention in periodontitis: proof-of-concept using a C5a receptor (CD88) antagonist. J Immunol 2012;189:5442-5448.
69. Breivik T, Gundersen Y, Gjermo P, Taylor SM, Woodruff TM, Opstad PK. Oral treatment with complement factor C5a receptor (CD88) antagonists inhibits experimental periodontitis in rats. J Periodont Res 2011;46:643-647.
70. Van Dyke TE, Levine MJ, Tabak LA, Genco RJ. Juvenile periodontitis as a model for neutrophil function: reduced binding of complement chemotactic fragment, C5a. J Dent Res 1983;62:870-872.
71. Short LL, Zoellner H, Hunter N. Association of amyloid P protein with pathology in periodontal tissues. J Oral Pathol Med 1994;23:354-357.
72. Paraskevas S, Huizinga JD, Loos BG. A systematic review and meta-analyses on C-reactive protein in relation to periodontitis. J Clin Periodontol 2008;35:277-290.
73. Lakshmanen R, Jayakumar ND, Sankari M, Padmalatha O, Varghese S. Estimation of pentraxin-3 levels in the gingival tissues of chronic and aggressive periodontitis participants - an in vivo study. J Periodontol 2014;85:290-297.
74. Inforzato A, Doni A, Barajon I et al. PTX3 as a paradigm for the interaction of pentraxins with the complement system. Semin Immunol 2013;25:79-85.
75. Glas J, Beynon V, Bachstein B et al. Increased plasma concentration of surfactant protein D in chronic periodontitis independent of SFTPD genotype: a potential role as a biomarker. Tissue Antigens 2008;72:21-28.
76. Silveyra P, Floros J. Genetic variant associations of human SP-A and SP-D with acute and chronic lung injury. Front Biosci (Landmark Ed) 2012;17:407-429.
77. Tegla CA, Cudrici C, Patel S et al. Membrane attack by complement: the assembly and biology of terminal complement complexes. Immunol Res 2011;51:45-60.
78. Singh B, Su YC, Riesbeck K. Vitronectin in bacterial pathogenesis: a host protein used in complement and cellular invasion. Mol Microbiol 2010;78:545-560.
79. Miwa T, Song WC. Membrane complement regulatory proteins: insight from animal studies and relevance to human diseases. Int Immunopharmacol 2001;1:445-459.
80. Barilla-LaBarca ML, Liszewski MK, Lambris JD, Hourcade D, Atkinson JP. (2002) Role of membrane cofactor protein (CD46) in regulation of C4b and C3b deposited on cells. J Immunol 2002;168:6298-6304.
81. Heinen S, Hartmann A, Lauer N et al. Factor H-related protein 1 (CFHR-1) inhibits complement C5 convertase activity and terminal complex formation. Blood 2009;112:2439-2447.
82. Attström R, Laurel AB, Lahsson U, Sjöholm A. Complement factors in gingival crevice material from healthy and inflamed gingiva in humans. J Periodont Res 1975;10:19-27.
83. Courts FJ, Boackle RJ, Fudenberg HH, Silverman MS. Detection of functional complement components in gingival crevicular fluid from humans with periodontal diseases. J Dent Res 1977;56:327-331.
84. Schenkein HA, Genco RJ. Gingival fluid and serum in periodontal diseases. I. Quantitative study of immunoglobulins, complement components, and other plasma proteins. J Periodontol 1977;48:772-777.
85. Schenkein HA, Genco RJ. Gingival fluid and serum in periodontal diseases. II. Evidence for cleavage of complement components C3, C3 proactivator (factor B) and C4 in gingival fluid. J Periodontol 1977;48:778-784.
86. Johnson RJ, Matthews JL, Stone MJ, Hurts WC, Newman JT. Immunopathology of periodontal disease. I. Immunologic profiles in periodontitis and juvenile periodontitis. J Periodontol 1980;51:705-712.
87. Ranney RR, Ruddy S, Tew JG, Welshimer HJ, Palcanis KG, Segreti A. Immunological studies of young adults with severe periodontitis. I. Medical evaluation and humoral factors. J Periodontol 1981;52:390-402.
88. Gebhard JD, Newman JT, Matthews JL, Hurt WC, Stone MJ. Immunopathology of periodontal disease. II. Immunofluorescent studies on the localized immune response in periodontitis and juvenile periodontitis. J Periodontol 1982;53:239-244.
89. Lally ET, McArthur WP, Baehni PC. Biosynthesis of complement in chronically inflamed gingiva. J Periodont Res 1982;17:257-262.
90. Patters MR, Niekrash CE, Lang NP. Assessment of complement cleavage in gingival fluid during experimental gingivitis in man. J Clin Periodontol 1989;16:33-37.
91. Toto PD, Lin L, Gargiulo A. Identification of C3a, IgG, IgM in inflamed human gingiva. J Dent Res 1978;57:696.
92. Toto PD, Lin LM, Gargiulo AW. Immunoglobulins and complement in human periodontitis. J Periodontol 1978;49:631-634.
93. Chisikovsky J, Toto PD, Gargiulo AW. C1q and C4 detection on bacterial plaque organisms. J Periodontol 1982;53:688-692.
94. Niekrash CE, Patters MR, Lang NP. The relationship of complement cleavage in gingival fluid to periodontal diseases. J Periodont Res 1984;19:622-627.
95. Niekrash CE, Patters MR. Assessment of complement cleavage in gingival fluid in humans with and without periodontal disease. J Periodont Res 1986;21:233-242.
96. Nikolopoulou-Papaconstantinou AA, Johannessen AC, Kristoffersen T. Deposits of immunoglobulins, complement, and immune complexes in inflamed human gingival. Acta Odontol Scand 1987;45:187-193.
97. Boackle RJ. The interaction of salivary secretions with the human complement system-a model for the study of host defense systems on inflamed mucosal surfaces. Crit Rev Oral Biol Med 1991;2:355-367.
98. Rautemaa R, Meri S. Protection of gingival epithelium against complement-mediated damage by strong expression of the membrane attack complex inhibitor protectin (CD59). J Dent Res 1996;75:568-574.
99. Snyderman R. Role for endotoxin and complement in periodontal tissue destruction. J Dent Res 1972;51:356-361.
100. Okada H, Silverman MS. Chemotactic activity in periodontal disease. I. The role of complement in monocyte chemotaxis. J Periodont Res 1979;14:20-25.
101. Okuda K, Takazoe I. Activation of complement by dental plaque. J Periodont Res 1980;15:232-239.
102. Watanabe K, Blew B, Scherer M et al. CD11b mRNA expression in neutrophils isolated from peripheral blood and gingival crevicular fluid. J Clin Periodontol 1997;24:814-822.
103. Krauss JL, Potempa J, Lambris JD, Hajishengallis G. Complementary Tolls in the periodontium: how periodontal bacteria modify complement and Toll-like receptor responses to prevail in the host. Periodontol 2000 2010;52:141-162.
104. Rorberts A, Shah M, Chapple IL. C-1 esterase inhibitor dysfunction localized to the periodontal tissues: clues to the role of stress in the pathogenesis of chronic periodontitis? J Clin Periodontol 2003;30:271-277.
105. Monefeldt K, Helgeland K, Tollefsen T. In vitro cleavage of serum complement protein C3: a comparison between patients with adult periodontitis and periodontally healthy persons. J Clin Periodontol 1995;22:45-51.
106. Anil S, Remani P, Vijayakumar T, Josph PA. Total hemolytic complement (CH50) and its fractions (C3 and C4) in the sera of diabetic patients with periodontitis. J Periodontol 1990;61:27-29.
107. Schenkein HA. Complement factor D-like activity of Porphyromonas gingivalis W83. Oral Microbiol Immunol 1991;6:216-220.
108. Potempa J, Pike RN. Corruption of innate immunity by bacterial proteases. J Innate Immun 2009;1:70-87.
109. Potempa M, Potempa J, Kantyka T et al. Interpain A, a cysteine proteinase from Prevotella intermedia, inhibits complement by degrading complement factor C3. PLoS Pathog 2009;5:e1000316. doi:10.1371/journal.ppat.1000316.
110. Guo Y, Nguyen KA, Potempa J. Dichotomy of gingipains action as virulence factors: from cleaving substrates with the precisions of a surgeon's knife to a meat chopper-like brutal degradation of proteins. Periodontol 2000 2010;54:14-44.
111. Malm S, Jusko M, Eick S, Potempa J, Riesbeck K, Blom AM. Acquisition of complement inhibitor serine protease factor I and its cofactors C4b-binding protein and factor H by Prevotella intermedia. PLoS ONE 2012;7:e34852. doi:10.1371/journal.pone.0034852.
112. McDowell JV, Lankford J, Stamm L, Sadlon T, Gordon DL, Marconi RT. Demonstration of factor H-like protein 1 binding to Treponema denticola, a pathogen associated with periodontal disease in humans. Infect Immun 2005;73:7126-7132.
113. McDowell JV, Huang B, Fenno JC, Marconi RT. Analysis of a unique interaction between the complement regulatory protein factor H and the periodontal pathogen Treponema denticola. Infect Immun 2009;77:1417-1425.
114. Miller DP, Bell JK, McDowell JV et al. Structure of factor H-binding protein B (FhbB) of the periopathogen, Treponema Denticola: insights into progression of periodontal disease. J Biol Chem 2012;287:12715-12722.
115. Kurnivati K, Zhang W, Zhang K, Li C. A surface exposed neuraminidase affects complement resistance and virulence of the oral spirochaete Treponema denticola. Mol Microbiol 2013;89:842-856.
116. Yamazaki T, Miyamoto M, Yamada K, Okuda K, Ishihara K. Surface protease of Treponema denticola hydrolyzes C3 and influences function of polymorphonuclear leukocytes. Microbes Infect 2006;8:1758-1763.
117. Asakawa R, Komatsuzawa H, Kawai T et al. Outer membrane protein 100, a versatile virulence factor of Actinobacillus actinomycetemcomitans. Mol Microbiol 2003;50:1125-1139.
118. Jusko M, Potempa J, Karim AY et al. A metalloproteinase karilysin present in the majority of Tannerella forsythia isolates inhibits all pathways of the complement system. J Immunol 2012;188:2338-2349.
119. Karim AY, Kulczycka M, Kantyka T et al. A novel matrix metalloproteinase-like enzyme (karilysin) of the periodontal pathogen Tannerella forsythia ATCC 43037. Biol Chem 2010;391:105-117.
120. Shimoatahira N, Oogai Y, Kawada-Matsuo M et al. The surface layer of Tannerella forsythia contributes to serum resistance and oral coaggregation. Infect Immun 2013;81:1198-1206.
121. Pöllänen MT, Laine MA, Ihalin R, Uitto VJ. Host-bacteria crosstalk at the dentogingival junction. Int J Dentistry 2012;2012:821383. doi:10.1155/2012/821383.
122. Wingrove JA, DiScipio RG, Chen Z, Potempa J, Travis J, Hugli TE. Activation of complement components C3 and C5 by a cysteine proteinase (gingipain-1) from Porphyromonas (Bacteroides) gingivalis. J Biol Chem 1992;267:18902-18907.
123. Popadiak K, Potempa J, Riesbeck K, Blom AM. Biphasic effect of gingipains from Porphyromonas gingivalis on the human complement system. J Immunol 2007;178:7242-7250.
124. Wang M, Krauss JL, Domon H et al. Microbial hijacking of complement-toll-like receptor crosstalk. Sci Signal 2010;3:ra11 doi: 10.1126/scisignal.2000697.
125. Liang S, Krauss JL, Domon H et al. The C5a receptor impairs IL-12-dependent clearance of Porphyromonas gingivalis and is required for induction of periodontal bone loss. J Immunol 2011;186:869-877.
126. Burns E, Bachrach G, Shapira L, Nussbaum G. Cutting Edge: TLR2 is required for the innate response to Porphyromonas gingivalis: activation leads to bacterial persistence and TLR2 deficiency attenuates induced alveolar bone resorption. J Immunol 2006;177:8296-8300.
127. Mahtout H, Curt S, Chandad F, Rouabhia M, Grenier D. Effect of periodontopathogen lipopolysaccharides and proinflammatory cytokines on CD46, CD55, and CD59 gene/protein expression by oral epithelial cells. FEMS Immunol Med Microbiol 2011;62:295-303.
128. Mahtout H, Chandad F, Rojo JM, Grenier D. Porphyromonas gingivalis mediates the shedding and proteolysis of complement regulatory protein CD46 expressed by oral epithelial cells. Oral Microbiol Immunol 2009;24:396-400.
129. Hajishengallis G, Shakhatreh MA, Wang M, Liang S. Complement receptor 3 blockade promotes IL-12-mediated clearance of Porphyromonas gingivalis and negates its virulence in vivo. J Immunol 2007;179:2359-2367.
130. Hans M, Hans VM. Toll-like receptors and their dual role in periodontitis: a review. J Oral Sci 2011;53:263-271.
131. Huang MT, Taxman DJ, Holley-Guthrie EA et al. Critical role of apoptotic speck protein containing a caspase recruitment domain (ASC) and NLRP3 in causing necrosis and ASC speck formation induced by Porphyromonas gingivalis in human cells. J Immunol 2009;182:2395-2404.
132. Belstrøm D, Holmstrup P, Damgaard C et al. The atherogenicbacterium Porphyromonas gingivalis evades circulating phagocytes by adhering to erythrocytes. Infect Immun 2011;79:1559-1565.
133. Cutler CW, Arnold RR, Schenkein HA. Inhibition of C3 and IgG proteolysis enhances phagocytosis of Porphyromonas gingivalis. J Immunol 1993;151:7016-7029.
134. Beikler T, Peters U, Prior K, Eisenacher M, Flemming TF. Gene expression in periodontal tissues following treatment. BMC Med Genomics 2008;1:30.
135. Niekrash CE, Patters MR. Simultaneous assessment of complement components C3, C4, and B and their cleavage products in human gingival fluid. II. Longitudinal changes during periodontal therapy. J Periodont Res 1985;20:268-275.
136. Maekawa T, Abe T, Hajishengallis E et al. Genetic and intervention studies implicating complement C3 as a major target for the treatment of periodontitis. J Immunol 2014;192:6020-6027.